Anthony Letai
Invented BH3 profiling, the functional test behind venetoclax's success, before becoming NCI director.
Haematologist-scientist from Dana-Farber whose laboratory developed BH3 profiling to measure mitochondrial apoptotic priming and predict response to BCL-2 inhibitors; appointed NCI director in 2025.
| Title | Journal | Year |
|---|---|---|
| Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy | Science | 2011 |
Pages like this
not linked directly; found by shared links- ProductSonrotoclax
Shares BH3 profiling (functional apoptosis testing), Intrinsic apoptosis (BCL-2 family), BCL-2, Venetoclax.
- PathwayExtrinsic apoptosis (death receptors)
Shares BH3 profiling (functional apoptosis testing), Intrinsic apoptosis (BCL-2 family), BCL-2, Venetoclax.
- TrialVIALE-A
Shares Intrinsic apoptosis (BCL-2 family), BCL-2, Venetoclax, Acute myeloid leukaemia.
- InstitutionWalter and Eliza Hall Institute of Medical Research
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia, Acute myeloid leukaemia.
- IdeaClear the zombie cells left behind by chemotherapy and radiotherapy
Shares Intrinsic apoptosis (BCL-2 family), BCL-2.
- TrialGLOW
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia.
- TermHallmark: resisting cell death
Shares Intrinsic apoptosis (BCL-2 family), BCL-2, Venetoclax.
- TrialCAPTIVATE
Shares BCL-2, Venetoclax, Chronic lymphocytic leukaemia.